Taking a GLP-1 receptor agonist was associated with a lower risk for cirrhosis and related complications in patients with ...

After insurance for New York City employees began covering GLP-1 weight-loss injectables, more than 1,000 city workers and ...

Study of those who started taking blockbuster weight loss drugs in 2021 suggests patients need support services, not just the ...

When food enters the digestive system, specialized cells in the small intestine release GLP-1, initiating a cascade of ...

Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity ...

For patients with opioid use disorder (OUD) and alcohol use disorder (AUD), prescriptions of glucose-dependent insulinotropic ...

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim ...

In a world increasingly focused on health and wellness, finding effective solutions for weight management can be challenging.

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter.

Reviewed by Dietitian Emily Lachtrupp, M.S., RD Ever since berberine made headlines last year for being touted as “nature’s ...

Moving ahead, Rob Rowe, Regional Research Director and Head of Global Strategy at a large US bank is ‘ tactically bullish ’ on the back of continuing tech recovery and the markets “pricing in a soft ...

The demand for bariatric operations dropped sharply last year as use of anti-obesity drugs such as Wegovy surged, study finds ...